# Single Oral Dose Escalation Study of DNDI-0690 in Healthy Subjects

> **NCT03929016** · PHASE1 · COMPLETED · sponsor: **Drugs for Neglected Diseases** · enrollment: 64 (actual)

## Conditions studied

- Visceral Leishmaniasis
- Cutaneous Leishmaniases

## Interventions

- **DRUG:** DNDI-0690
- **DRUG:** Placebo of DNDI-0690

## Key facts

- **NCT ID:** NCT03929016
- **Lead sponsor:** Drugs for Neglected Diseases
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-04
- **Primary completion:** 2019-12-06
- **Final completion:** 2020-07-02
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2022-12-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03929016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03929016, "Single Oral Dose Escalation Study of DNDI-0690 in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03929016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*